Skip to main navigation Skip to search Skip to main content

Selective Janus kinase inhibition preserves interferon-λ-mediated antiviral responses

  • Daniel Schnepf
  • , Stefania Crotta
  • , Thiprampai Thamamongood
  • , Megan Stanifer
  • , Laura Polcik
  • , Annette Ohnemus
  • , Juliane Vier
  • , Celia Jakob
  • , Miriam Llorian
  • , Hans Henrik Gad
  • , Rune Hartmann
  • , Birgit Strobl
  • , Susanne Kirschnek
  • , Steeve Boulant
  • , Martin Schwemmle
  • , Andreas Wack
  • , Peter Staeheli
  • Medical Center – University of Freiburg
  • University of Freiburg
  • The Francis Crick Institute
  • University of Heidelberg
  • University of Aarhus
  • University of Veterinary Medicine

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

Inflammatory diseases are frequently treated with Janus kinase (JAK) inhibitors to diminish cytokine signaling. These treatments can lead to inadvertent immune suppression and may increase the risk of viral infection. Tyrosine kinase 2 (TYK2) is a JAK family member required for efficient type I interferon (IFN-α/β) signaling. We report here that selective TYK2 inhibition preferentially blocked potentially detrimental type I IFN signaling, whereas IFN-λ-mediated responses were largely preserved. In contrast, the clinically used JAK1/2 inhibitor baricitinib was equally potent in blocking IFN-α/β- or IFN-λ-driven responses. Mechanistically, we showed that epithelial cells did not require TYK2 for IFN-λ-mediated signaling or antiviral protection. TYK2 deficiency diminished IFN-α- induced protection against lethal influenza virus infection in mice but did not impair IFN-λ-mediated antiviral protection. Our findings suggest that selective TYK2 inhibitors used in place of broadly acting JAK1/2 inhibitors may represent a superior treatment option for type I interferonopathies to counteract inflammatory responses while preserving antiviral protection mediated by IFN-λ.

Original languageEnglish
Article numbereabd5318
JournalScience Immunology
Volume6
Issue number59
DOIs
Publication statusPublished - May 2021
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Selective Janus kinase inhibition preserves interferon-λ-mediated antiviral responses'. Together they form a unique fingerprint.

Cite this